<?xml version='1.0' encoding='utf-8'?>
<document id="15179410"><sentence text="Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients."><entity charOffset="49-60" id="DDI-PubMed.15179410.s1.e0" text="enfuvirtide" /></sentence><sentence text="Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells"><entity charOffset="0-11" id="DDI-PubMed.15179410.s2.e0" text="Enfuvirtide" /></sentence><sentence text=" This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients"><entity charOffset="33-44" id="DDI-PubMed.15179410.s3.e0" text="enfuvirtide" /></sentence><sentence text="" /><sentence text="An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively"><entity charOffset="127-135" id="DDI-PubMed.15179410.s5.e0" text="caffeine" /><entity charOffset="137-150" id="DDI-PubMed.15179410.s5.e1" text="chlorzoxazone" /><entity charOffset="152-159" id="DDI-PubMed.15179410.s5.e2" text="dapsone" /><entity charOffset="161-172" id="DDI-PubMed.15179410.s5.e3" text="debrisoquin" /><entity charOffset="174-177" id="DDI-PubMed.15179410.s5.e4" text="INN" /><entity charOffset="179-191" id="DDI-PubMed.15179410.s5.e5" text="debrisoquine" /><entity charOffset="198-209" id="DDI-PubMed.15179410.s5.e6" text="mephenytoin" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e0" e2="DDI-PubMed.15179410.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e1" e2="DDI-PubMed.15179410.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e2" e2="DDI-PubMed.15179410.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e2" e2="DDI-PubMed.15179410.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e2" e2="DDI-PubMed.15179410.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e2" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e2" e2="DDI-PubMed.15179410.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e3" e2="DDI-PubMed.15179410.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e3" e2="DDI-PubMed.15179410.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e3" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e3" e2="DDI-PubMed.15179410.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e4" e2="DDI-PubMed.15179410.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e4" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e4" e2="DDI-PubMed.15179410.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e5" e2="DDI-PubMed.15179410.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15179410.s5.e5" e2="DDI-PubMed.15179410.s5.e6" /></sentence><sentence text=" Dapsone was used to assess N-acetyltransferase activity"><entity charOffset="1-8" id="DDI-PubMed.15179410.s6.e0" text="Dapsone" /></sentence><sentence text=" Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6"><entity charOffset="92-103" id="DDI-PubMed.15179410.s7.e0" text="enfuvirtide" /></sentence><sentence text=" Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7"><entity charOffset="1-12" id="DDI-PubMed.15179410.s8.e0" text="Enfuvirtide" /></sentence><sentence text=" Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6)" /><sentence text="" /><sentence text="The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0"><entity charOffset="50-61" id="DDI-PubMed.15179410.s11.e0" text="enfuvirtide" /></sentence><sentence text="33 versus 0" /><sentence text="34; 90% confidence interval [CI] for ratio of least squares means, 0" /><sentence text="88-1" /><sentence text="09), CYP2D6 (0" /><sentence text="72 versus 0" /><sentence text="71; 90% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.15179410.s17.e0" text="CI" /></sentence><sentence text="97-1" /><sentence text="06), and N-acetyltransferase (0" /><sentence text="35 versus 0" /><sentence text="39; 90% CI, 0"><entity charOffset="8-9" id="DDI-PubMed.15179410.s21.e0" text="CI" /></sentence><sentence text="82-0" /><sentence text="98) were bioequivalent" /><sentence text=" The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0"><entity charOffset="51-62" id="DDI-PubMed.15179410.s24.e0" text="enfuvirtide" /></sentence><sentence text="76 versus 0" /><sentence text="81; 90% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.15179410.s26.e0" text="CI" /></sentence><sentence text="71-1" /><sentence text="17), CYP2E1 (1" /><sentence text="3 versus 1" /><sentence text="2; 90% CI, 0"><entity charOffset="7-9" id="DDI-PubMed.15179410.s30.e0" text="CI" /></sentence><sentence text="87-1" /><sentence text="29), and CYP2C19 (93 versus 81" /><sentence text="8; 90% CI, 0"><entity charOffset="7-9" id="DDI-PubMed.15179410.s33.e0" text="CI" /></sentence><sentence text="98-1" /><sentence text="28) were not bioequivalent but were not substantially different" /><sentence text="" /><sentence text="Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19"><entity charOffset="0-11" id="DDI-PubMed.15179410.s37.e0" text="Enfuvirtide" /></sentence><sentence text=" The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low" /><sentence text="" /></document>